Answers are grounded in this paper and cite their sources.
Industrial emission events often release complex mixtures of volatile organic compounds (VOCs) into the environment at temporarily elevated concentrations. Risk assessment of VOC mixtures remains a significant challenge, as regulatory evaluations typically rely on single-chemical toxicity data and animal-derived points of departure (PODs) that are often limited in availability and labor intensive to generate. To address this gap, we evaluated a human bronchial epithelial air–liquid interface (ALI) model as a human-relevant new approach methodology (NAM) for characterizing the acute biological effects of VOC mixtures, using benzene, acrolein, acetone, and acetaldehyde as a representative mixture. Barrier permeability, cytotoxicity, and expression of select genes were assessed as endpoints to predict mixture toxicity following an acute inhalation exposure. Barrier permeability and cytotoxicity emerged as the most robust and practical PODs, demonstrating greater sensitivity than transcriptional markers. Notably, the VOC mixture produced greater-than additive effects even when individual component concentrations were below established regulatory guideline values. Although concentration-addition modeling predicted effective concentrations within an order of magnitude of observed responses, PODs derived from barrier permeability and cytotoxicity indicated that mixture toxicity was underestimated. These findings highlight limitations of traditional additivity assumptions for VOC mixtures, particularly those containing highly electrophilic aldehydes such as acrolein and acetaldehyde. Overall, this work supports the integration of human-relevant, barrier-based endpoints within NAMs for acute respiratory risk assessment of complex VOC mixtures.
No takes yet. Share an insight, caveat, or question.
Lampe et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: